For research use only. Not for therapeutic Use.
LY315920 (Cat.No:I002247) is a small molecule inhibitor used in biomedical research. It is known to target the ATP-binding site of Janus kinase 2 (JAK2), a key enzyme involved in cytokine signaling. By inhibiting JAK2, LY315920 can modulate various signaling pathways and has been studied for its potential therapeutic applications in inflammatory and autoimmune diseases, as well as certain types of cancers.
| Catalog Number | I002247 |
| CAS Number | 172732-68-2 |
| Synonyms | 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid |
| Molecular Formula | C₂₁H₂₀N₂O₅ |
| Purity | ≥95% |
| Target | Phospholipase |
| Solubility | DMSO: ≥ 32 mg/mL |
| Storage | 3 years -20℃ powder |
| IC50 | 7 nM |
| IUPAC Name | 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid |
| InChI | InChI=1S/C21H20N2O5/c1-2-14-19(20(26)21(22)27)18-15(9-6-10-16(18)28-12-17(24)25)23(14)11-13-7-4-3-5-8-13/h3-10H,2,11-12H2,1H3,(H2,22,27)(H,24,25) |
| InChIKey | BHLXTPHDSZUFHR-UHFFFAOYSA-N |
| SMILES | CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N |
| Reference | </br>1:Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Lewin M, Samuel S, Merkel J, Bickler P.Toxins (Basel). 2016 Aug 25;8(9). pii: E248. doi: 10.3390/toxins8090248. PMID: 27571102 Free PMC Article</br>2:Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators..JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836. PMID: 24247616 </br>3:Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture. De Luca D, Vendittelli F, Trias J, Fraser H, Minucci A, Gentile L, Perez-Gil J, Conti G, Antonelli M, Capoluongo ED.Curr Pharm Biotechnol. 2013;14(4):445-8. PMID: 23590147 </br>4:Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS. De Luca D, Minucci A, Piastra M, Cogo PE, Vendittelli F, Marzano L, Gentile L, Giardina B, Conti G, Capoluongo ED.PLoS One. 2012;7(10):e47066. doi: 10.1371/journal.pone.0047066. Epub 2012 Oct 11. PMID: 23071714 Free PMC Article</br>5:Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. Rosenson RS, Fraser H, Goulder MA, Hislop C.Cardiovasc Drugs Ther. 2011 Dec;25(6):539-44. doi: 10.1007/s10557-011-6344-2. PMID: 21989792 </br>6:Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury. De Luca D, Minucci A, Trias J, Tripodi D, Conti G, Zuppi C, Capoluongo E; Study Group on Secretory Phospholipase in Pediatrics..J Clin Pharmacol. 2012 May;52(5):729-37. doi: 10.1177/0091270011405498. Epub 2011 May 20. PMID: 21602519 </br>7:Varespladib. [No authors listed]Am J Cardiovasc Drugs. 2011;11(2):137-43. doi: 10.2165/11533650-000000000-00000. Review. PMID: 21446779 </br>8:After FRANCIS: next steps in the clinical evaluation of varespladib methyl. Rosenson RS.Future Cardiol. 2011 Jan;7(1):11-8. doi: 10.2217/fca.10.118. PMID: 21174506 </br>9:Varespladib: targeting the inflammatory face of atherosclerosis. Arsenault BJ, Boekholdt SM, Kastelein JJ.Eur Heart J. 2011 Apr;32(8):923-6. doi: 10.1093/eurheartj/ehq385. Epub 2010 Nov 25. No abstract available. PMID: 21112895 </br>10:Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D.J Am Coll Cardiol. 2010 Sep 28;56(14):1079-88. doi: 10.1016/j.jacc.2010.06.015. Erratum in: J Am Coll Cardiol. 2011 Mar 29;57(13):1501. PMID: 20863951 Free Article |
